Research
Education
Solutions
Sign In
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
The Mina & Everard Goodman Faculty of Life Sciences,
The Nanotechnology Institute
Doron Gerber has not added Biography.
If you are Doron Gerber and would like to personalize this page please email our Author Liaison for assistance.
Chirality-independent protein-protein recognition between transmembrane domains in vivo.
Journal of molecular biology Sep, 2002 | Pubmed ID: 12225743
The composition rather than position of polar residues (QxxS) drives aspartate receptor transmembrane domain dimerization in vivo.
Biochemistry Mar, 2004 | Pubmed ID: 14979727
Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization.
The Journal of biological chemistry May, 2004 | Pubmed ID: 14985340
Structural adaptation of the glycophorin A transmembrane homodimer to D-amino acid modifications.
Journal of molecular biology May, 2004 | Pubmed ID: 15123435
Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide: possible recognition of the fusion complex.
The Journal of biological chemistry Nov, 2004 | Pubmed ID: 15339935
Hetero-assembly between all-L- and all-D-amino acid transmembrane domains: forces involved and implication for inactivation of membrane proteins.
Journal of molecular biology Nov, 2004 | Pubmed ID: 15533450
From genome to antivirals: SARS as a test tube.
Drug discovery today Mar, 2005 | Pubmed ID: 15749283
D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Jul, 2005 | Pubmed ID: 15837719
The identification of a minimal dimerization motif QXXS that enables homo- and hetero-association of transmembrane helices in vivo.
The Journal of biological chemistry Jul, 2005 | Pubmed ID: 15911619
HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.
The Journal of clinical investigation Aug, 2005 | Pubmed ID: 16007266
T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Feb, 2007 | Pubmed ID: 17185749
A structurally altered D,L-amino acid TCRalpha transmembrane peptide interacts with the TCRalpha and inhibits T-cell activation in vitro and in an animal model.
Biochemistry Mar, 2007 | Pubmed ID: 17288453
Specificity in transmembrane helix-helix interactions mediated by aromatic residues.
The Journal of biological chemistry Jul, 2007 | Pubmed ID: 17488729
Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis.
Nature biotechnology Sep, 2008 | Pubmed ID: 18758449
An in vitro microfluidic approach to generating protein-interaction networks.
Nature methods Jan, 2009 | Pubmed ID: 19098921
De novo identification and biophysical characterization of transcription-factor binding sites with microfluidic affinity analysis.
Nature biotechnology Sep, 2010 | Pubmed ID: 20802496
Transmembrane domains interactions within the membrane milieu: Principles, advances and challenges.
Biochimica et biophysica acta Apr, 2012 | Pubmed ID: 22155642
Sperm epidermal growth factor receptor (EGFR) mediates α7 acetylcholine receptor (AChR) activation to promote fertilization.
The Journal of biological chemistry Jun, 2012 | Pubmed ID: 22577141
Libraries and Information System of Bar-Ilan University
Bar-Ilan University
Yair Glick*,1,
Dorit Avrahami*,1,
Efrat Michaely1,
Doron Gerber1
1The Mina & Everard Goodman Faculty of Life Sciences, The Nanotechnology Institute, Bar-Ilan University
Privacy
Terms of Use
Policies
Contact Us
Recommend to library
JoVE NEWSLETTERS
JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Authors
Librarians
Access
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved